Discover how molecular glue degraders harness the ubiquitin–proteasome system to destroy oncogenic proteins once considered “undruggable.” Learn what molecular glues are, how they differ from traditional inhibitors, and why they’re poised to transform precision oncology.
Learn what proteolysis-targeting chimeras (PROTACs) are, how they work as small-molecule protein degraders, and why they outperform classic inhibitors by accessing undruggable targets, driving deep protein knockdown, and enabling next-generation cancer therapies like ARV-110.
Learn how molecular glue small molecules rewire protein–protein interactions, enable targeted protein degradation, and unlock “undruggable” targets in oncology, neurology, and immunology. Explore their mechanism, history from thalidomide to rational design, and role in AI-driven drug discovery.
Discover how molecular glues are transforming drug discovery by enabling targeted protein degradation of previously “undruggable” targets. Learn their mechanism, advantages over PROTACs, and emerging AI‑driven design strategies in oncology and immunology.
Learn how targeted protein degradation (TPD) uses PROTACs and molecular glue degraders to hijack the ubiquitin–proteasome system, eliminate disease-causing proteins, and expand the “druggable” proteome beyond traditional small molecule inhibitors.
Learn how next‑generation small molecule PROTACs go beyond inhibition to eliminate disease‑driving proteins. Explore their mechanism, improved selectivity, oral bioavailability, and ability to target previously “undruggable” proteins using advanced ternary complex design and diversified E3 ligases.
Learn how PROTAC small molecules are redefining cancer therapy by harnessing targeted protein degradation to eliminate “undruggable” oncogenic drivers, overcome resistance, and expand the frontier of small molecule oncology.
Discover how next-generation small molecule PROTACs work as “molecular assassins” by harnessing the ubiquitin–proteasome system to degrade disease-driving proteins, overcome drug resistance, and expand drug discovery beyond traditional inhibitors.
Learn what PROTACs (Proteolysis-Targeting Chimeras) are, how they hijack the ubiquitin–proteasome system to degrade disease-driving proteins, and why these small molecule degraders are game-changers for targeting undruggable cancer proteins and overcoming drug resistance.
Learn how PROTAC small molecule drugs are redefining cancer therapy by degrading, not just inhibiting, oncogenic proteins. Explore the PROTAC mechanism, their role in expanding the druggable cancer proteome, and their potential to overcome resistance in precision oncology.
- 1
- 2